Company / Current Assets
Aligos Therapeutics, Inc. Current Assets History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$82.9M
FY2025
5-year range
$62.1M / $204.4M
FY2021-FY2025
Trend
+33.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 6 years, ranging from $62M in FY2024 to $250M in FY2020.
Based on SEC 10-K filings.
$83M in FY2025 with a 5-year CAGR of -19.8%.
Declined from $141M to $83M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -14.7%
- 5-Year CAGR
- -19.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -19.8%, indicating a declining trend.
- In FY2025, current assets increased 33.3% year-over-year.
- Peak current assets was recorded in FY2020.
- Lowest current assets in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.9M | +33.3% |
| FY2024 | $62.1M | -56.0% |
| FY2023 | $141.1M | +5.6% |
| FY2022 | $133.5M | -34.7% |
| FY2021 | $204.4M | -18.2% |
| FY2020 | $250.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026